Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpFinancial_Report.xls
10-K - FORM 10-K - AMERICAN CRYOSTEM Corpacryo_10k12.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR9.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR4.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR1.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR8.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR3.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR2.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR6.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR14.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR28.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR25.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR18.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR12.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR37.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR22.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR29.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR32.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR36.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR11.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR15.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR23.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR31.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR13.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR35.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR33.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR30.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR24.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR39.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR16.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR19.htm
EX-31.1 - EXHIBIT 31.1 - AMERICAN CRYOSTEM Corpex31_1.htm
EX-31.2 - EXHIBIT 31.2 - AMERICAN CRYOSTEM Corpex31_2.htm
EX-32.1 - EXHIBIT 32.1 - AMERICAN CRYOSTEM Corpex32_1.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR5.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR21.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR38.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR34.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR26.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR20.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR27.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR10.htm
XML - IDEA: XBRL DOCUMENT - AMERICAN CRYOSTEM CorpR17.htm
v2.4.0.6
NOTE 1. Organization of the Company and Significant Accounting Policies
12 Months Ended
Sep. 30, 2012
Basis of Presentation and Significant Accounting Policies [Text Block]

Note 1. Organization of the Company and Significant Accounting Policies


American CryoStem Corporation (the “Company”) is a publicly held corporation formed on March 13, 2009 in the state of Nevada as R&A Productions Inc. (R&A)


In April 2011, R&A purchased substantially all the assets and liabilities of American CryoStem Corporation (ACS) for 21 million shares of common stock. ACS was deemed to be the accounting acquirer. At that time, the former operations of R&A were discontinued and the name of the Company was changed to American CryoStem Corporation.


The Company is in the business of collecting adipose tissue, processing it to separate the adult stem cells, and preparing such stem cells for long-term storage. The process allows individuals to preserve their stem cells for future personal use in cellular therapy. The adipose derived stem cells are prepared and stored in their raw form without manipulation, bio-generation or the addition of biomarkers or other materials, making them suitable for use in cellular treatments and therapies offered by existing and planned treatment centers worldwide. Individualized collection and storage of adult stem cells provides personalized medicine solutions by making the patient’s own preserved stem cells available for future cellular therapies.


Use of Estimates - The preparation of the financial statements in conformity with United States generally accepted accounting principles (“GAAP”) uniformly applied requires management to make reasonable estimates and assumptions that affect the reported amounts of the assets and liabilities and disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses at the date of the financial statements and for the period they include. Actual results may differ from these estimates.


Cash and interest bearing deposits - For the purpose of calculating changes in cash flows, cash includes all cash balances and highly liquid short-term investments with an original maturity of three months or less.


Revenue Recognition – The Company recognizes revenue from the processing of adipose tissue into usable stem cells once all the procedures have been performed and the client sample has been stored in the Company’ cryogenic storage tank. Storage revenues for stored client samples are recognized on an annual basis on the anniversary date of the storage.


Long Lived Assets - The Company reviews for the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount.


Fixed Assets Fixed assets are stated at cost. Depreciation expense is computed using the straight-line method over the estimated useful life of the assets, which is estimated as follows:


Office equipment 5 years
Lab equipment & furniture   7 years
Lab software   5 years

Income taxes - The Company accounts for income taxes in accordance with generally accepted accounting principles which require an asset and liability approach to financial accounting and reporting for income taxes. Deferred income tax assets and liabilities are computed annually for differences between financial statement and income tax bases of assets and liabilities that will result in taxable income or deductible expenses in the future based on enacted tax laws and rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets and liabilities to the amount expected to be realized. Income tax expense is the tax payable or refundable for the period adjusted for the change during the period in deferred tax assets and liabilities.


The Company follows the accounting requirements associated with uncertainty in income taxes using the provisions of Financial Accounting Standards Board (FASB) ASC 740, Income Taxes. Using that guidance, tax positions initially need to be recognized in the financial statements when it is more likely than not the positions will be sustained upon examination by the tax authorities. It also provides guidance for derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. As of September 30, 2012, the Company has no uncertain tax positions that qualify for either recognition or disclosure in the financial statements. All tax returns from fiscal years 2009 to 2011 are subject to IRS audit.


Recently Issued Accounting Pronouncements


In July 2012, the FASB issued changes to the testing of indefinite-lived intangible assets for impairment, similar to the goodwill changes issued in September 2011. These changes provide an entity the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not (more than 50%) that the fair value of an indefinite-lived intangible asset is less than its carrying amount. Such qualitative factors may include the following: macroeconomic conditions; industry and market considerations; cost factors; overall financial performance; and other relevant entity-specific events. If an entity elects to perform a qualitative assessment and determines that an impairment is more likely than not, the entity is then required to perform the existing two-step quantitative impairment test, otherwise no further analysis is required. An entity also may elect not to perform the qualitative assessment and, instead, proceed directly to the two-step quantitative impairment test. These changes become effective for any indefinite-lived intangible asset impairment test performed on January 1, 2013 or later, although early adoption is permitted. Upon adoption of these changes, management plans to proceed directly to the two-step quantitative test for indefinite-lived intangible assets. As these changes should not affect the outcome of the impairment analysis of an indefinite-lived intangible asset, management has determined these changes will not have a material impact on the financial statements.